Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1969 1
1973 1
1976 4
1977 1
1978 3
1979 2
1980 10
1981 6
1982 5
1983 4
1984 5
1985 3
1986 9
1987 3
1988 6
1989 8
1990 5
1991 19
1992 12
1993 10
1994 20
1995 12
1996 10
1997 31
1998 32
1999 29
2000 31
2001 40
2002 46
2003 44
2004 51
2005 53
2006 68
2007 64
2008 72
2009 46
2010 52
2011 76
2012 64
2013 67
2014 71
2015 86
2016 82
2017 94
2018 108
2019 122
2020 125
2021 146
2022 149
2023 150
2024 61

Text availability

Article attribute

Article type

Publication date

Search Results

1,960 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Dermatitis, atopic, 7"
Page 1
Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, Di Giorgio S, Arents BWM, Burton T, Spuls PI, Schmitt J, Flohr C. Drucker AM, et al. JAMA Dermatol. 2022 May 1;158(5):523-532. doi: 10.1001/jamadermatol.2022.0455. JAMA Dermatol. 2022. PMID: 35293977 Free PMC article.
OBJECTIVE: To compare reported measures of efficacy and assessments of safety in clinical trials of systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis. DATA SOURCES: The Cochrane Central Register of Controlled Tr …
OBJECTIVE: To compare reported measures of efficacy and assessments of safety in clinical trials of systemic treatments for atopic …
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z, Xu C, Pierce E, Morgan-Cox M, Garcia Gil E, Silverberg JI. Blauvelt A, et al. Br J Dermatol. 2023 May 24;188(6):740-748. doi: 10.1093/bjd/ljad022. Br J Dermatol. 2023. PMID: 36994947 Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). ...EASI 75 was maintained b …
OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atop …
Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L, Pérez-Herrera LC, Díaz Martinez JP, Brignardello-Petersen R, Sadeghirad B, Wong MM, Ceccacci R, Zhao IX, Basmaji J, MacDonald M, Chu X, Islam N, Gao Y, Izcovich A, Asiniwasis RN, Boguniewicz M, De Benedetto A, Capozza K, Chen L, Ellison K, Frazier WT, Greenhawt M, Huynh J, LeBovidge J, Lio PA, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel JM, Smith Begolka W, Wang J, Wheeler KE, Gardner DD, Schneider L. Chu DK, et al. J Allergy Clin Immunol. 2023 Dec;152(6):1493-1519. doi: 10.1016/j.jaci.2023.08.030. Epub 2023 Sep 9. J Allergy Clin Immunol. 2023. PMID: 37678572 Free article.
BACKGROUND: Atopic dermatitis (AD) is a common skin condition with multiple topical treatment options, but uncertain comparative effects. ...Random-effects network meta-analyses addressed AD severity, itch, sleep, AD-related quality of life, flares, and harms …
BACKGROUND: Atopic dermatitis (AD) is a common skin condition with multiple topical treatment options, but uncertain comparati …
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R. Silverberg JI, et al. JAMA Dermatol. 2020 Aug 1;156(8):863-873. doi: 10.1001/jamadermatol.2020.1406. JAMA Dermatol. 2020. PMID: 32492087 Free PMC article. Clinical Trial.
IMPORTANCE: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE: To investigate the efficacy and safety of a …
IMPORTANCE: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy …
Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses.
Nakajima S, Kabata H, Kabashima K, Asano K. Nakajima S, et al. Allergol Int. 2020 Apr;69(2):197-203. doi: 10.1016/j.alit.2020.01.001. Epub 2020 Jan 21. Allergol Int. 2020. PMID: 31974038 Free article. Review.
TSLP is thus considered a master regulator of type 2 immune responses at the barrier surfaces of skin and the respiratory/gastrointestinal tract. Indeed, genetic, experimental, and clinical evidence suggests that the TSLP-TSLPR pathway is associated with the pathogenesis o …
TSLP is thus considered a master regulator of type 2 immune responses at the barrier surfaces of skin and the respiratory/gastrointestinal t …
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL. Papp K, et al. J Am Acad Dermatol. 2021 Oct;85(4):863-872. doi: 10.1016/j.jaad.2021.04.085. Epub 2021 May 4. J Am Acad Dermatol. 2021. PMID: 33957195 Free article. Clinical Trial.
BACKGROUND: Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD). OBJECTIVE: To evaluate 8-week efficacy and safety in 2 phase 3 studies of RUX cream in patients with AD. ... …
BACKGROUND: Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with ato …
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Blauvelt A, et al. J Am Acad Dermatol. 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. J Am Acad Dermatol. 2022. PMID: 34416294 Free article. Clinical Trial.
BACKGROUND: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. OBJECTIVE: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal, and response …
BACKGROUND: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. OBJECTIVE: We …
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab-JP01 Study Group. Kabashima K, et al. N Engl J Med. 2020 Jul 9;383(2):141-150. doi: 10.1056/NEJMoa1917006. N Engl J Med. 2020. PMID: 32640132 Clinical Trial.
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic d …
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved …
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. Reich K, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885
BACKGROUND: Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at 12 or 16 weeks in phase 3 studies with a manageable safety profile. ...RESULTS: As of the data cut-off, ~70% and ~45% of patients received abrocitinib for 36 and 48 w …
BACKGROUND: Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at 12 or 16 weeks in phase 3 …
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrándiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M. Worm M, et al. JAMA Dermatol. 2020 Feb 1;156(2):131-143. doi: 10.1001/jamadermatol.2019.3617. JAMA Dermatol. 2020. PMID: 31876900 Free PMC article. Clinical Trial.
IMPORTANCE: The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). OBJECTIVE: To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatmen …
IMPORTANCE: The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis ( …
1,960 results